DEF 14A: REGENXBIO Inc. Announces Annual Meeting of Stockholders and Proxy Statement Details

REGENXBIO Inc. has released its proxy statement for the upcoming Annual Meeting of Stockholders to be held on May 30, 2025, outlining key proposals including the election of directors, ratification of the accounting firm, and approval of the 2025 Equity Incentive Plan.

Summary

• REGENXBIO Inc. will hold its Annual Meeting of Stockholders on May 30, 2025, in Rockville, Maryland.
• Stockholders will vote on the election of four Class I directors, including Allan Fox, Alexandra Glucksmann, Curran Simpson, and Jennifer Zachary.
• The meeting will also include a vote to ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• An advisory vote on executive compensation and the frequency of future advisory votes on executive compensation will be conducted.
• Stockholders will also vote to approve the REGENXBIO Inc. 2025 Equity Incentive Plan.
• The company's Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10K are available online.
• In 2024, REGENXBIO achieved key enrollment milestones for ABBV-RGX-314, delivered on RGX-202 milestones, and announced positive data for RGX-121.
• The company successfully implemented a strategic pipeline prioritization and corporate restructuring, targeting cost reductions in excess of $50.0 million in 2024.
• REGENXBIO ended 2024 with $244.9 million in cash, cash equivalents, and marketable securities.
• In the first quarter of 2025, the company announced a strategic partnership with Nippon Shinyaku, receiving a $110.0 million upfront payment.

Sentiment

Score: 7

Explanation: The document presents a balanced view of REGENXBIO's progress, highlighting both achievements and ongoing strategic initiatives. The financial strength and key milestones reached contribute to a positive outlook.

Positives

• The company achieved key enrollment milestones with ABBV-RGX-314 ATMOSPHERE and ASCENT pivotal clinical trials.
• Positive new data was announced from multiple trials in the ABBV-RGX-314 program.
• RGX-202 milestones were delivered, including initiating a pivotal (Phase III) trial of AFFINITY DUCHENNE.
• The pivotal phase of the CAMPSIITE trial of RGX-121 achieved its primary endpoint.
• A successful pre-Biologics License Application (BLA) meeting for RGX-121 was announced.
• Strategic alternatives were achieved for other clinical stage product candidates through out-licensing agreements.
• A strategic partnership to develop and commercialize RGX-121 and RGX-111 was announced in January 2025.
• Targeted cost reductions in excess of $50.0 million were achieved in 2024.
• The company successfully transitioned senior leadership roles.
• REGENXBIO ended 2024 with $244.9 million in cash, cash equivalents and marketable securities.
• A $110.0 million upfront payment was received under the collaboration with Nippon Shinyaku in March 2025.

Future Outlook

The company will continue to prioritize the development of ABBV-RGX-314, RGX-202 and RGX-121, while seeking strategic alternatives for other clinical stage programs and investing in its pre-clinical pipeline.

Industry Context

The document highlights REGENXBIO's position as a pioneer in AAV gene therapy, operating in a competitive biotechnology landscape focused on rare and retinal diseases.

Comparison to Industry Standards

• The document mentions peer group companies used for benchmarking executive compensation, including 2seventy bio, Denali Therapeutics, and Ultragenyx Pharmaceutical.
• The company's commitment to corporate responsibility is illustrated by its Leadership in Energy and Environmental Design Gold certified headquarters.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The proposals aim to enhance shareholder value through effective corporate governance and strategic initiatives.
• Employees: The 2025 Equity Incentive Plan is designed to attract and retain top talent.
• Patients: Advancing the clinical pipeline has the potential to improve healthcare delivery for millions of people.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will continue to advance its late-stage pipeline and seek strategic partnerships.
• REGENXBIO will continue to invest in its pre-clinical pipeline.

Key Dates

Keywords

REGENXBIO, Annual Meeting, Proxy Statement, Directors, Executive Compensation, Equity Incentive Plan, PricewaterhouseCoopers, Gene Therapy, Clinical Trials, Financial Performance, ABBV-RGX-314, RGX-202, RGX-121, Nippon Shinyaku, AbbVie, Corporate Governance, Stockholders